ello, everyone, and how are you today? We are just fine, thank you, now that the short person has made the trip to the local schoolhouse and the officials mascots are quietly ensconced in their official snoozing positions. As for us, we are quaffing the usual cups of stimulation — we are trying vanilla creme brulee, for those who track this sort of thing — and scrounging about for interesting items. On that note, here are some tidbits. Have a lovely day and, as always, do keep in touch …

John Kapoor, the founder of Insys Therapeutics (INSY) who was indicted last week for allegedly participating in a scheme to bribe doctors and illegally market the Subsys opioid painkiller, resigned on Monday as chairman of Akorn (AKRX), another drug maker that he has largely controlled. In a brief statement, the company, which recently agreed to be acquired by Fresnius Kabi, says his departure is not related to “operations, policies or practices.”

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy